Cellectis bioresearch launches Compact TALEN™
the next generation of TAL effector nucleases

Paris (France), September 23, 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of a monomeric Compact TALEN™, that allows efficient transfection and genome editing in sensitive cells.

Transfection of sensitive cells such as primary cells, plant cells and iPS cells is the major limitation for efficient genome editing. To breakdown this barrier, Cellectis scientists have developed a monomeric TALEN™, distributed under the name Compact TALEN™. In contrast to Custom TALEN™, the monomeric Compact TALEN™ requires the expression of only one DNA or RNA molecule to be active. This exquisite property, not only ease DNA/RNA cell transfection but offers a tremendous advantage to scientist who have to use viral shuttles for vectorization. The Cellectis Group is the first in its sector to develop and market such a tool. This technology greatly simplifies the design and synthesis as well as the therapeutic delivery of nucleases.

This new product based on Cellectis’ proprietary TAL effector nuclease technology makes it possible to target specific DNA segments using just a single molecule, as shown in the innovative study on ultra-precise Compact TALEN™ published in the scientific journal Nature Communications:

Compact designer TALENs for efficient genome engineering.
Cellectis, Research and Development

Compact TALEN™ constitutes a breakthrough in the fields of genome engineering and synthetic biology. This technology is covered by an international patent application published under WO 2012/138927.

For further information please visit our website www.cellectis-bioresearch.com or contact@cellectis-bioresearch.com

About Cellectis bioresearch
Established in 2008 as a subsidiary of Cellectis, Cellectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning Custom TALEN™ Services. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.

About Cellectis
Founded in France in 1999, the Cellectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bioenergies. Cellectis was cofounded by André Choulika, its Chairman and CEO, and is now one of the world’s top companies in the field of genome engineering, with revenue of $27 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, toxicity testing, and
regenerative medicine. Cellectis has a solid background in the large-scale handling of stem cells up until their maturation and differentiation into functional cell types. We employ a workforce of 230 people at 5 sites worldwide: New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States, Gothenburg in Sweden, and Paris & Evry in France. The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. Our clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris. For more information, visit our website: www.cellectis.com.

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Cellectis
Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
media@cellectis.com